



December 1, 2015



Relmada Therapeutics to Present at LD Micro Main Event

Company Presentation on December 3, 2015 at 9:00 a.m. Pacific Time

NEW YORK, Dec. 1, 2015 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that the company will present at the LD Micro Main Event. The conference will be held December 1-3 at the Luxe Sunset Boulevard Hotel in Los Angeles, CA. Sergio Traversa, CEO of Relmada Therapeutics, will present on Thursday, December 3, at 9:00 am Pacific time (12:00 pm Eastern Time).



A live webcast of the presentation will be available through the Company's website at www.relmada.com. Please register at least 10 minutes prior to the start of the presentation to ensure timely access. The webcast and presentation will also be archived on the website for 90 days after the conference.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of pain. The Company has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for

neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. The Company's product development efforts are guided by the internationally recognized scientific expertise of its research team. The Company's approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs. For more information, please visit Relmada's website at: www.relmada.com.

Forward-Looking Statements

This news release contains "forward-looking statements." These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contact

Media Contact:

Nick Lamplough
Joele Frank, Wilkinson Brimmer Katcher
212-355-4449

Investor Contact:

Michael Becker, SVP of Finance and Corporate Development
Relmada Therapeutics Inc.
Tel: 212-376-5776
mbecker@relmada.com

Logo - <https://photos.prnewswire.com/prnh/20150113/168770LOGO>

To view the original version on PR Newswire, visit <http://www.prnewswire.com/news-releases/relmada-therapeutics-to-present-at-ld-micro-main-event-300186069.html>

SOURCE Relmada Therapeutics, Inc.